SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
[HTML][HTML] Peptide and peptide-based inhibitors of SARS-CoV-2 entry
To date, no effective vaccines or therapies are available against the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of the coronavirus …
syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of the coronavirus …
Oral antiviral treatments for COVID-19: opportunities and challenges
L Rahmah, SO Abarikwu, AG Arero, M Essouma… - Pharmacological …, 2022 - Springer
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …
and prevent disease progression to a more severe form. However, the timing of antiviral …
Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells
Abstract Coronavirus disease 2019 (COVID-19) initiated in December 2019 in Wuhan,
China and became pandemic causing high fatality and disrupted normal life calling world …
China and became pandemic causing high fatality and disrupted normal life calling world …
Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches
M Gioia, C Ciaccio, P Calligari, G De Simone… - Biochemical …, 2020 - Elsevier
In the Fall of 2019 a sudden and dramatic outbreak of a pulmonary disease (Coronavirus
Disease COVID-19), due to a new Coronavirus strain (ie, SARS-CoV-2), emerged in the …
Disease COVID-19), due to a new Coronavirus strain (ie, SARS-CoV-2), emerged in the …
SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in their requirements for receptor expression and proteolytic activation
BF Hörnich, AK Großkopf, S Schlagowski… - Journal of …, 2021 - Am Soc Microbiol
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infects cells
through interaction of its spike protein (SARS2-S) with angiotensin-converting enzyme 2 …
through interaction of its spike protein (SARS2-S) with angiotensin-converting enzyme 2 …
Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates
L Rodrigues, R Bento Cunha, T Vassilevskaia… - Molecules, 2022 - mdpi.com
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
The transmembrane protease TMPRSS2 as a therapeutic target for COVID-19 treatment
L Wettstein, F Kirchhoff, J Münch - International Journal of Molecular …, 2022 - mdpi.com
TMPRSS2 is a type II transmembrane protease with broad expression in epithelial cells of
the respiratory and gastrointestinal tract, the prostate, and other organs. Although the …
the respiratory and gastrointestinal tract, the prostate, and other organs. Although the …
Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection
P Fuentes-Prior - Journal of Biological Chemistry, 2021 - ASBMB
The ongoing COVID-19 pandemic has already caused over a million deaths worldwide, and
this death toll will be much higher before effective treatments and vaccines are available …
this death toll will be much higher before effective treatments and vaccines are available …
Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
The entry of the coronavirus SARS-CoV-2 into human lung cells can be inhibited by the
approved drugs camostat and nafamostat. Here we elucidate the molecular mechanism of …
approved drugs camostat and nafamostat. Here we elucidate the molecular mechanism of …